Institutional investors purchased a net $6.3 million shares of HALO during the quarter ended June 2017. This may signal that the smart money is gaining interest in this company as the 72.80% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
THE VANGUARD GROUP, INC. Bought 287.4 Thousand shares of Halozyme Therapeutics Inc